ALSO NOTED: Merck HIV med gets FDA nod; Health Canada warns on Abbott diet drug;

> As expected, Merck got the FDA's OK for its new HIV drug Isentress, expected to account for 8 percent of its worldwide sales in the next three to five years. The drug is earmarked for those whose treatment with other meds is failing. Release

> Health Canada is warning doctors against the heart risks associated with Abbott Laboratories weight-loss drug Meridia--again. Report

> AstraZeneca stock bounced upward after Morgan Stanley boosted its price target for the shares. Report

> German drugs distributor Celesio is negotiating to buy a majority stake in Russia's Protek Holding, which has a 24 percent share of that country's pharma distribution market and owns its second-largest pharmacy chain. Report

> Ireland's United Drug has bought U.S.-based Alliance Healthcare Information, a sales-and-marketing services firm. Report

And Finally... How would you like a lead-laced kiss? The FDA is reviewing claims that 20 brand-name lipsticks contain dangerous levels of the heavy metal. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.